Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Andrea S. Melani. (2018) Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review. Expert Opinion on Pharmacotherapy 19:14, pages 1603-1611.
Read now
Read now
Craig LaForce, Eric Derom, Ulrich Bothner, Isabel M Kloer, Matthias Trampisch & Roland Buhl. (2018) Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 1819-1831.
Read now
Read now
Articles from other publishers (4)
Roy Pleasants. 2020. Cardiac Considerations in Chronic Lung Disease. Cardiac Considerations in Chronic Lung Disease
161
212
.
Yen-Fu Chen, Yi-Ching Cheng, Chien-Hong Chou, Chung-Yu Chen & Chong-Jen Yu. (2019) Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study. BMC Pulmonary Medicine 19:1.
Crossref
Crossref
Joy Creaser-Thomas, Vignesh Rajasundaram & Gwyneth A Davies. 2017. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
161
171
.
Jens Markus Borghardt, Benjamin Weber, Alexander Staab, Christina Kunz & Charlotte Kloft. (2016) Model‐based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation. British Journal of Clinical Pharmacology 82:3, pages 739-753.
Crossref
Crossref